Arena Pharmaceuticals, Inc. (ARNA) Financial Statements (2025 and earlier)
Company Profile
| Business Address |
6154 NANCY RIDGE DRIVE SAN DIEGO, CA 92121 |
| State of Incorp. | DE |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)Annual | Quarterly
| 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | 9/30/2020 Q3 | 6/30/2020 Q2 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments, including: | 800,000 | 1,000,000 | 1,100,000 | 1,104,041 | 1,167,864 | 1,170,634 | |||
| Cash and cash equivalent | 386,653 | 514,177 | 432,978 | 219,544 | 460,145 | 550,176 | |||
| Short-term investments | 385,014 | 457,359 | 655,846 | 884,497 | 707,719 | 620,458 | |||
| Other undisclosed cash, cash equivalents, and short-term investments | 28,333 | 28,464 | 11,176 | ||||||
| Other undisclosed current assets | (9,080) | (9,565) | 21,605 | 35,266 | 34,383 | 33,296 | |||
| Total current assets: | 790,920 | 990,435 | 1,121,605 | 1,139,307 | 1,202,247 | 1,203,930 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 19,558 | 20,388 | 21,129 | 22,090 | 22,913 | 23,769 | |||
| Long-term investments and receivables | 52,953 | 34,419 | 33,286 | 94,838 | |||||
| Long-term investments | 52,953 | 34,419 | 33,286 | 94,838 | |||||
| Other noncurrent assets | 37,596 | 39,417 | 41,202 | 29,323 | 17,097 | 17,213 | |||
| Total noncurrent assets: | 110,107 | 94,224 | 62,331 | 51,413 | 73,296 | 135,820 | |||
| TOTAL ASSETS: | 901,027 | 1,084,659 | 1,183,936 | 1,190,720 | 1,275,543 | 1,339,750 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 30,037 | 23,417 | 21,980 | 35,351 | 26,697 | 18,339 | |||
| Employee-related liabilities | 15,878 | 10,445 | 6,777 | 18,846 | 15,297 | 11,249 | |||
| Accounts payable | 6,937 | 3,785 | 9,547 | 12,004 | 7,681 | 2,155 | |||
| Accrued liabilities | 7,222 | 9,187 | 5,656 | 4,501 | 3,719 | 4,935 | |||
| Other undisclosed current liabilities | 23,318 | 41,420 | 25,527 | 22,726 | 25,199 | 23,532 | |||
| Total current liabilities: | 53,355 | 64,837 | 47,507 | 58,077 | 51,896 | 41,871 | |||
| Noncurrent Liabilities | |||||||||
| Liabilities, other than long-term debt | 9,466 | 9,962 | 10,410 | 10,963 | 11,352 | 11,744 | |||
| Other liabilities | 9,466 | 9,962 | 10,410 | 10,963 | 11,352 | 11,744 | |||
| Other undisclosed noncurrent liabilities | 41,211 | ||||||||
| Total noncurrent liabilities: | 9,466 | 9,962 | 10,410 | 52,174 | 11,352 | 11,744 | |||
| Total liabilities: | 62,821 | 74,799 | 57,917 | 110,251 | 63,248 | 53,615 | |||
| Equity | |||||||||
| Equity, attributable to parent | 800,721 | 971,080 | 1,085,992 | 1,080,469 | 1,169,927 | 1,242,637 | |||
| Common stock | 6 | 6 | 6 | 6 | 6 | 6 | |||
| Additional paid in capital | 2,769,148 | 2,743,225 | 2,711,930 | 2,587,494 | 2,553,939 | 2,528,112 | |||
| Accumulated other comprehensive income | 122 | 92 | 204 | 700 | 1,552 | 2,651 | |||
| Accumulated deficit | (1,968,555) | (1,772,243) | (1,626,148) | (1,507,731) | (1,385,570) | (1,288,132) | |||
| Total equity: | 800,721 | 971,080 | 1,085,992 | 1,080,469 | 1,169,927 | 1,242,637 | |||
| Other undisclosed liabilities and equity | 37,485 | 38,780 | 40,027 | 42,368 | 43,498 | ||||
| TOTAL LIABILITIES AND EQUITY: | 901,027 | 1,084,659 | 1,183,936 | 1,190,720 | 1,275,543 | 1,339,750 | |||
Income Statement (P&L) ($ in thousands)Annual | Quarterly
| 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | 9/30/2020 Q3 | 6/30/2020 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 37 | 20 | ||||||
| Gross profit: | 37 | 20 | ||||||
| Operating expenses | (194,485) | (144,391) | (131,993) | (135,338) | (98,822) | (87,823) | ||
| Operating loss: | (194,485) | (144,391) | (131,993) | (135,301) | (98,802) | (87,823) | ||
| Nonoperating income (expense) | (1,827) | (1,704) | 13,576 | 13,140 | 1,364 | 2,895 | ||
| Investment income, nonoperating | 205 | 328 | 14,559 | 14,171 | 1,825 | 3,065 | ||
| Other nonoperating income (expense) | (1,001) | (981) | 90 | 65 | 659 | 974 | ||
| Interest and debt expense | (1,031) | (1,051) | (1,073) | (1,096) | (1,120) | (1,144) | ||
| Loss from continuing operations before equity method investments, income taxes: | (197,343) | (147,146) | (119,490) | (123,257) | (98,558) | (86,072) | ||
| Other undisclosed income from continuing operations before income taxes | 1,096 | 1,120 | 1,144 | |||||
| Loss from continuing operations: | (197,343) | (147,146) | (119,490) | (122,161) | (97,438) | (84,928) | ||
| Loss before gain (loss) on sale of properties: | ✕ | (197,343) | (147,146) | (119,490) | (122,161) | (97,438) | (84,928) | |
| Net loss: | (197,343) | (147,146) | (119,490) | (122,161) | (97,438) | (84,928) | ||
| Other undisclosed net income attributable to parent | 1,031 | 1,051 | 1,073 | |||||
| Net loss available to common stockholders, diluted: | (196,312) | (146,095) | (118,417) | (122,161) | (97,438) | (84,928) | ||
Comprehensive Income ($ in thousands)Annual | Quarterly
| 12/31/2021 Q4 | 9/30/2021 Q3 | 6/30/2021 Q2 | 3/31/2021 Q1 | 12/31/2020 Q4 | 9/30/2020 Q3 | 6/30/2020 Q2 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (197,343) | (147,146) | (119,490) | (122,161) | (97,438) | (84,928) | ||
| Other comprehensive income (loss) | (44) | (162) | (331) | (944) | (1,151) | 2,495 | ||
| Comprehensive loss: | (197,387) | (147,308) | (119,821) | (123,105) | (98,589) | (82,433) | ||
| Other undisclosed comprehensive income, net of tax, attributable to parent | 1,105 | 1,101 | 908 | 92 | 52 | 31 | ||
| Comprehensive loss, net of tax, attributable to parent: | (196,282) | (146,207) | (118,913) | (123,013) | (98,537) | (82,402) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.